… In-stent restenosis and neoatherosclerosis after … BBR (50 µmol/L) inhibited chlamydia
pneumoniae infection … that by inhibiting the activity of the mammalian target of rapamycin (mTOR) …

… Chlamydia was developed. Later, when cell culture methods for … In this work, only the name
Chlamydia pneumoniae is used. … An inclusion can also be released from the cell only partly …

… Chlamydia pneumoniae is known to induce atherosclerotic inflammation, pro-… was partially
reversed by the autophagy inhibitor 3-MA. The double-edged sword nature of autophagy may …

… , which will inform the development of increasingly … varicella-zoster virus, Chlamydia
pneumoniae, Mycoplasma spp. … ), and mammalian target of rapamycin (mTOR) signalling …

… , and angiography can help define the anatomy of partial … 0.4-0.6% in patients who have
sirolimus drug eluting stent [3] . The … Multiple case reports were published in the past for in-stent …

… and acinar development were impaired at birth, but partially … While inhibition of mTORC1
by rapamycin prior to RANKL … to the inhibition of SMC proliferation as a way of preventing …

… , leading to thrombosis that can partly or entirely block the … , sirolimus, biolimus, everolimus,
etc.) may be used for … containing liposomes effectively inhibited in-stent neointimal growth in …

… The nanoscience and nanotechnology may be one of the tools for the development of a …
aid in preventing drugs from being tarnished in the gastrointestinal region and help the delivery …

… The usual dose of sirolimus may be too large for neonates. … such as a history of syncope, an
EP study can help determine if … The enema lead to partial rectal prolapse that spontaneously …

… ], which might suggest that HDL function may play a more pivotal part in the prevention against
… Indeed, in general, patients with BMS are likely to develop in‐stent restenosis (ISR) early …